Tag: LLC

Ensemble, les plateformes technologiques d’inspection avancées de NDT Global et d’Entegra permettront d’élargir leurs capacités et leur portée sur le marché, créant un chef de file mondial dans l’inspection interne des pipelines

ATLANTA, July 31, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Albany International Corp. (“Albany International” or the “Company”) (NYSE: AIN) complied with federal securities laws. On July 31, 2025, Albany International reported operating results for its second quarter 2025, noting its “performance was largely impacted by certain timing and operational issues[.]” Following this news, the price of the Company’s stock dropped. 

FARGO, N.D., July 31, 2025 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian), a leader in developing solutions for health care programs, is pleased to announce the North Dakota Health and Human Services has re-awarded Noridian the Medicaid Call Center contract, reaffirming Noridian’s role in elevating the state’s Medicaid program. This contract renewal extends Noridian’s partnership with North Dakota, ensuring continued high-quality service for Medicaid inquiries, including claims payment, claims submission and prior authorization.

Dallas, TX, July 31, 2025 (GLOBE NEWSWIRE) -- Vivakor, Inc. (Nasdaq: VIVK) (“Vivakor” or the “Company”), an integrated provider of energy transportation, storage, reuse, and remediation service, today announced the record date of August 20, 2025 for its previously disclosed plan to issue a special dividend to Vivakor shareholders.

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share. The underwriters will not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 5,700,000 shares of its common stock. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125.4 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares of common stock in the offering are to be sold by Prime Medicine. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions.